Akela Pharma has announced completion of a private placement totaling $2,310,000 that it will use primarily for expansion of spray drying and hot melt extrusion capabilities at its subsidiary, PharmaForm. Although PharmaForm specializes in solid dosage forms, it also offers services for nasal sprays and dry powder formulation development.
The parent company, Akela, discontinued its Taifun inhaled fentanyl development program in August 2011 to focus on PharmaForm.
Read the Akela press release.
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
